CliffBio
biologic

Enflonsia

clesrovimab-cfor

Loss of exclusivityJune 2037projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameEnflonsia
Active ingredientclesrovimab-cfor
Strength105MG/0.7ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJune 2025
Marketing statusRx

More from Merck Sharp & Dohme LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Enflonsia patent cliff — loss of exclusivity June 2037 | CliffBio